Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

125.36 -0.60 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
A Preview Of Krystal Biotech's Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
5 Analysts Have This to Say About Krystal Biotech
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
5 Analysts Have This to Say About Krystal Biotech
Via Benzinga
Analyst Ratings for Krystal Biotech
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023
Via Benzinga
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Expert Ratings for Krystal Biotech
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
Up 48% in 2023, Is This Biotech Stock a Buy?
How much longer can this biotech's run last? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
Why Shares of Krystal Biotech Are Rising Monday
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem. 
Via MarketBeat
Exposures Product Safety
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic  
Via Benzinga
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday. 
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS